clinical trial · NCT05234567
A Prospective Sub-Study of the Global Hypophosphatasia Registry
Alexion Pharmaceuticals, Inc.·—·recruiting·n = 30
HypophosphatasiaAsfotase Alfa
brief summary
In this prospective observational sub-study, participants with pediatric-onset hypophosphatasia (HPP) (perinatal/infantile- or juvenile-onset) of any age will be followed for a minimum of 5 years at sites in the United States and potentially 1 or 2 other countries.
started
Aug 25, 2022
primary completion
Jul 18, 2028
completion
Jul 18, 2028
last updated
Feb 9, 2026
official title
A Prospective Observational Sub-Study of the Global Hypophosphatasia Registry to Describe the Potential Risk of Immune-Mediated Loss of Pharmacological Effect of Asfotase Alfa in Participants With Hypophosphatasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol